Patents Examined by Peter Paras, Jr.
  • Patent number: 9901082
    Abstract: Genetically modified non-human animals are provided that may be used to model human hematopoietic cell development, function, or disease. The genetically modified non-human animals comprise a nucleic acid encoding human IL-6 operably linked to an IL-6 promoter. In some instances, the genetically modified non-human animal expressing human IL-6 also expresses at least one of human M-CSF, human IL-3, human GM-CSF, human SIRPa or human TPO. In some instances, the genetically modified non-human animal is immunodeficient. In some such instances, the genetically modified non-human animal is engrafted with healthy or diseased human hematopoietic cells. Also provided are methods for using the subject genetically modified non-human animals in modeling human hematopoietic cell development, function, and/or disease, as well as reagents and kits thereof that find use in making the subject genetically modified non-human animals and/or practicing the subject methods.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: February 27, 2018
    Assignees: Regeneron Pharmaceuticals, Inc., Yale University, Institute for Research in Biomedicine (IRB)
    Inventors: Richard Flavell, Till Strowig, Markus G. Manz, Chiara Borsotti, Madhav Dhodapkar, Andrew J. Murphy, Sean Stevens, George D. Yancopoulos
  • Patent number: 9803219
    Abstract: Described is an adenovirus derived helper virus which may comprise the adenoviral DNA sequences for E2a, S4 (orf6), the VA1 RNA gene, and the parvovirus VP capsid gene unit. Also described is a method of efficiently preparing a recombinant parvovirus (particle) which is based on the use of various adenoviral derived helper viruses/vectors.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: October 31, 2017
    Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventors: Nazim El-Andaloussi, Antonio Marchini, Jean Rommelaere, Barbara Leuchs, Max Endele
  • Patent number: 9102914
    Abstract: This disclosure relates generally to methods, apparatuses, and cellular compositions and cellular products that use a unique trophoblast-containing 3D matrix as a compartmental chamber for growing embryoid bodies that can be induced to differentiate into organ-specific cell types.
    Type: Grant
    Filed: February 3, 2011
    Date of Patent: August 11, 2015
    Assignee: EMPIRE TECHNOLOGY DEVELOPMENT LLC
    Inventor: Yansong Gu
  • Patent number: 9045731
    Abstract: This invention provides an isolated stem cell that has been modified to provide, enhance or contain the functional characteristics of the sarcoplasmic reticulum (SR). The isolated stem cells are modified in one or more of the following manners: by expressing a calcium channel protein; by expressing a calcium pump protein such as the sarcro/endoplasmic reticulum Ca2+-ATPase (SERCA) protein; by inhibiting or downregulating expression of the Na+/Ca+ exchanger (NCX) protein; by expressing a calcium handling protein; by expressing a transverse (t-tubule; and/or by expressing a transverse (t-tubule biogenic protein. After the cell has been modified, it may be expanded to a substantially homogenous population of these cells or alternatively, differentiated to a more mature cell type. Compositions containing these cells and population of cells are also provided by this invention.
    Type: Grant
    Filed: September 11, 2008
    Date of Patent: June 2, 2015
    Assignee: The Regents of the University of California
    Inventors: Ronald Li, Chung-wah Siu, Deborah K. Lieu, Jing Liu
  • Patent number: 9029141
    Abstract: Disclosure of a mammalian cytoplasmic donor cell line. Disclosure of a patient specific cell line. Methods to obtain a mammalian cytoplasmic donor cell line by fusing a differentiated mammalian cell and a functionally enucleated mammalian embryonic cell line. Methods to obtain a mammalian cytoplasmic donor cell line by fusing a differentiated mammalian cell and a functionally enucleated human cancer cell. Methods to obtain a patient specific cell line of a cell type similar to a mammalian cytoplasmic donor cell line by functionally enucleating the mammalian cytoplasmic donor cell line and fusing the functionally enucleated mammalian cytoplasmic donor cell line with a differentiated cell obtained from the patient. A method of treatment of a human patient by administering the patient-specific cell line to the patient.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: May 12, 2015
    Inventor: Thiru V. Gopal
  • Patent number: 9029336
    Abstract: An isolated nucleic acid molecule comprising a nucleotide sequence encoding a transcriptional enhancer of cytochrome P450 (P450) CYP3A4 production or expression, and uses of the nucleic acid molecule for screening compounds for xenobiotic induction of CYP3A4 expression in cells and animals.
    Type: Grant
    Filed: December 2, 2009
    Date of Patent: May 12, 2015
    Assignee: The University of Sydney
    Inventors: Christopher Liddle, Bryan James Goodwin
  • Patent number: 8962587
    Abstract: The present invention provides a method for decreasing the level of methylation of Oct4 promoter in a target cell, comprising transfecting the target cell with the combination of Oct4 cDNA and SirT1 cDNA. The invention also provides a method for inducing cytoprotective responses of a target cell, comprising transfecting the target cell with the combination of Oct4 cDNA and SirT1 cDNA. The invention further provides a pharmaceutical composition comprising Oct4 cDNA and SirT1 cDNA, or a polynucleotide comprising Oct4 cDNA and SirT1 cDNA.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: February 24, 2015
    Assignee: Taipei Veterans General Hospital
    Inventors: Shih-Hwa Chiou, Jong-Yuh Cherng
  • Patent number: 8809617
    Abstract: The present invention relates to methods and compositions for high content drug screening in C. elegans which may be used to identify compounds that treat disorders associated with protein aggregation.
    Type: Grant
    Filed: September 14, 2010
    Date of Patent: August 19, 2014
    Assignee: The University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Stephen C. Pak, David H. Perlmutter, Gary A. Silverman
  • Patent number: 8623645
    Abstract: Disclosed herein are cell cultures comprising definitive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified definitive endoderm cells as well as methods for enriching, isolating and purifying definitive endoderm cells from other cell types.
    Type: Grant
    Filed: March 30, 2009
    Date of Patent: January 7, 2014
    Assignee: Viacyte, Inc.
    Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Emmanuel E. Baetge
  • Patent number: 8603811
    Abstract: Disclosed herein are cell cultures and enriched cell populations of endocrine precursor cells, immature pancreatic hormone-expressing cells and mature pancreatic hormone-expressing cells. Also disclosed herein are methods of producing such cell cultures and cell populations.
    Type: Grant
    Filed: October 17, 2011
    Date of Patent: December 10, 2013
    Assignee: ViaCyte, Inc.
    Inventors: Kevin A. D'Amour, Anne Bang, Emmanuel E. Baetge
  • Patent number: 8592642
    Abstract: Disclosed is an evaluation method which can rapidly discriminate a Dao?/? homozygote from a large number of animals produced in a mating experiment between a DAO enzyme deficient mouse and other disease model mice, to rapidly perform a quantitative measurement of the D-amino acids contained in a large number of samples. The invention provides a method for evaluating the effect of a test condition on a mouse tissue, or cultured tissue cells derived from the tissue. The method comprises the steps of: providing a Dao1?/? mouse or the like; exposing the tissue from the Dao1?/? mouse or the like, to the test condition; and analyzing the effect of exposing the tissue from the Dao1?/? mouse or the like, to the test condition.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: November 26, 2013
    Assignees: Kyushu University, National University Corporation, Shiseido Company, Ltd.
    Inventors: Kenji Hamase, Kiyoshi Zaitsu, Masashi Mita, Yutaka Ashida, Yousuke Toujo
  • Patent number: 8586024
    Abstract: The present invention is directed to long-lasting therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes a therapeutic polypeptide, such as erythropoietin or interferon alpha.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: November 19, 2013
    Assignee: Medgenics Medical Israel Ltd.
    Inventors: Andrew L. Pearlman, Baruch S. Stern
  • Patent number: 8586307
    Abstract: The present invention provides methods for detecting epigenetic, multigenerational DNA alterations caused by toxicants such as endocrine disruptor agents in a subject. The practice of the present invention can be used to diagnose and/or treat a subject having the identified DNA alterations by developing therapeutics, to prevent or delay the onset of associated diseases and/or dysfunctions.
    Type: Grant
    Filed: May 22, 2006
    Date of Patent: November 19, 2013
    Inventor: Michael K. Skinner
  • Patent number: 8574905
    Abstract: Disclosed herein are methods for producing liver precursor cells as well as hepatocyte cells form pluripotent and/or multipotent cells. Also disclosed herein are methods of enriching isolating and/or purifying liver precursor cells and/or hepatocyte cells. Further disclosed are compositions comprising cell cultures and cell populations that are enriched for liver precursor cells or hepatocyte cells.
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: November 5, 2013
    Assignee: ViaCyte, Inc.
    Inventors: Kevin D'Amour, Emmanuel E. Baetge
  • Patent number: 8574904
    Abstract: The present invention provides a method for producing mesenchymal cells for production of mesenchymal cells for formation of a tooth, the method comprising: culturing totipotent stem cells in the presence of a differentiation inducer to produce a cell population after differentiation induction treatment, the cell population containing CD44-positive and CD29-positive cells or CD44-positive and CD106-positive cells; and selecting, from the cell population after the differentiation induction treatment, the CD44-positive and CD29-positive cells or CD44-positive and CD106-positive cells as the mesenchymal cells for the formation of the tooth.
    Type: Grant
    Filed: January 18, 2008
    Date of Patent: November 5, 2013
    Assignee: Organ Technologies Inc.
    Inventors: Takashi Tsuji, Ritsuko Morita
  • Patent number: 8565898
    Abstract: A biologic intervention method and apparatus generates a persistent modification to an AV node that is physiologically stable after the agent has matured but is alterable with subsequent application of an agent. Specifically, the generic agent is used to modulate a node in a cardiac conduction system including rate control using one and a combination of a family of K+ channel or equivalent. Specifically, the channel is implemented to slow conduction by generating an outward current during optimization of action potential and repolarization phase thus decreasing the current that is available to excite downstream cells. A Kv 1.3 channel, for example, may be used as the biologic channel. The invention enables reversal of the modulation or adjustment for various heart rates (BPM) based on medical and patient-specific needs.
    Type: Grant
    Filed: April 28, 2005
    Date of Patent: October 22, 2013
    Assignee: Medtronic, Inc.
    Inventors: Vinod Sharma, Daniel C. Sigg
  • Patent number: 8552254
    Abstract: The present invention provides novel methods of maintaining genetic stability of non-human animal inbred strains. In the methods, pedigree-tracked cryopreserved embryos or gametes or pre-gametes derived from a foundation colony are produced and used to re-establish the foundation colony at appropriate intervals.
    Type: Grant
    Filed: October 26, 2009
    Date of Patent: October 8, 2013
    Assignee: The Jackson Laboratory
    Inventors: Michael V. Wiles, Robert Taft, Eva M. Eicher, Shannon Byers
  • Patent number: 8530636
    Abstract: Methods and compositions for the rapid and reversible destabilizing of specific proteins in vivo using cell-permeable, synthetic molecules are described.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: September 10, 2013
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Thomas J. Wandless, Laura A. Banaszynski, Mark A. Sellmyer, Christopher H. Contag, Steven H. Thorne
  • Patent number: 8454948
    Abstract: The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin.
    Type: Grant
    Filed: January 10, 2012
    Date of Patent: June 4, 2013
    Assignee: Medgenics Medical Israel Ltd.
    Inventors: Andrew L. Pearlman, Baruch S. Stern
  • Patent number: 8415153
    Abstract: Methods for differentiating human pluripotent stem cells into islet-like cells are provided. In certain embodiments, the methods utilize sequential culturing of the human pluripotent stem cells with certain factors to produce islet-like cells. In certain embodiments, the population of cells produced by the methods is further enriched for islet-like cells.
    Type: Grant
    Filed: May 25, 2007
    Date of Patent: April 9, 2013
    Assignee: Geron Corporation
    Inventors: Anish Sen Majumdar, JianJie Jiang, Melinda Au